Advertisement

ADVERTISEMENT

Prostate Cancer

Dr. Tward
Videos
Dr Tward Discusses 2022 Anticipated Prostate Cancer Advancements Part 2
02/28/2022
In part two of this series, Dr Tward, MD, Huntsman Cancer Institute, discusses use of the Polaris test to prognosticate metastasis of men undergoing radiation therapy with prostate cancer, as well as ongoing efforts to further advance...
In part two of this series, Dr Tward, MD, Huntsman Cancer Institute, discusses use of the Polaris test to prognosticate metastasis of men undergoing radiation therapy with prostate cancer, as well as ongoing efforts to further advance...
In part two of this series, Dr...
02/28/2022
Oncology
Dr Shen
Videos
Dr Shen Highlights Apalutamide Therapy for Mature Patients With Advanced Prostate Cancer
09/21/2021
John Shen, MD, UCLA, discusses a combined analysis of TITAN & SPARTAN, apalutamide (APA) therapy for older patients with advanced prostate cancer, presented at the 2021 ESMO Congress.
John Shen, MD, UCLA, discusses a combined analysis of TITAN & SPARTAN, apalutamide (APA) therapy for older patients with advanced prostate cancer, presented at the 2021 ESMO Congress.
John Shen, MD, UCLA, discusses a...
09/21/2021
Oncology
Test Your Knowledge
Quiz: Somatic Sequencing in Metastatic Prostate Cancer
07/28/2021
True or False: Somatic sequencing of metastatic tissue in prostate cancer is challenging due to the bone‑trophic nature of advanced prostate cancer, as well as the diagnostic yield from sequencing bone metastases being quite low.
True or False: Somatic sequencing of metastatic tissue in prostate cancer is challenging due to the bone‑trophic nature of advanced prostate cancer, as well as the diagnostic yield from sequencing bone metastases being quite low.
True or False: Somatic...
07/28/2021
Oncology
Conference Coverage
Real-world PSA Progression After Enzalutamide or Abiraterone for Metastatic CRPC
06/24/2021
A real-world study presented at the virtual 2021 ASCO Annual Meeting evaluated prostate-specific antigen pattern progression and its association with OS among patients with metastatic CRPC who were treated with enzalutamide or abiraterone.
A real-world study presented at the virtual 2021 ASCO Annual Meeting evaluated prostate-specific antigen pattern progression and its association with OS among patients with metastatic CRPC who were treated with enzalutamide or abiraterone.
A real-world study presented at...
06/24/2021
Journal of Clinical Pathways
Dr Tagawa
Videos
Dr Tagawa Discusses Study Results of Actinium J591 for mCRPC
06/22/2021
Scott Tagawa, MD, MS, FACP, discusses the background and findings of a phase 1 study on the use of a PSMA-targeted radionuclide therapy for patients with mCRPC.
Scott Tagawa, MD, MS, FACP, discusses the background and findings of a phase 1 study on the use of a PSMA-targeted radionuclide therapy for patients with mCRPC.
Scott Tagawa, MD, MS, FACP,...
06/22/2021
Oncology
Conference Coverage
Physician- and Patient-Reported Outcomes Among Five Radiotherapy Methods for Prostate Cancer
06/21/2021
A recent study comparing radiotherapy methods for prostate cancer suggests that physician-reported toxicities may be lower for patients treated with high-dose-rate brachytherapy, and patient-reported outcomes may be worse for those treated...
A recent study comparing radiotherapy methods for prostate cancer suggests that physician-reported toxicities may be lower for patients treated with high-dose-rate brachytherapy, and patient-reported outcomes may be worse for those treated...
A recent study comparing...
06/21/2021
Journal of Clinical Pathways
Dr
Interview
Dr Schweizer Talks Concordance of DDR Mutations in Paired Primary, Metastatic Prostate Cancer Samples
06/15/2021
Michael Schweizer, MD, Seattle Cancer Care Alliance, discusses a prostate cancer study that was presented at the 2021 ASCO Annual Meeting.
Michael Schweizer, MD, Seattle Cancer Care Alliance, discusses a prostate cancer study that was presented at the 2021 ASCO Annual Meeting.
Michael Schweizer, MD, Seattle...
06/15/2021
Oncology
dr a
Videos
Dr Agarwal Discusses Final Analysis Results of the TITAN Study - Part 2
06/15/2021
In part two of this video series, Neeraj Agarwal, MD, shares final analysis results from the TITAN clinical trial being presented at the virtual 2021 ASCO Annual Meeting.
In part two of this video series, Neeraj Agarwal, MD, shares final analysis results from the TITAN clinical trial being presented at the virtual 2021 ASCO Annual Meeting.
In part two of this video...
06/15/2021
Oncology
dr agarwal
Videos
Dr Agarwal Discusses Final Analysis Results of the TITAN Study - Part 1
06/15/2021
In part one of this video series, Neeraj Agarwal, MD, discusses HRQoL and patient-reported outcomes at final analysis of the TITAN study being presented at the virtual 2021 ASCO Annual Meeting.
In part one of this video series, Neeraj Agarwal, MD, discusses HRQoL and patient-reported outcomes at final analysis of the TITAN study being presented at the virtual 2021 ASCO Annual Meeting.
In part one of this video...
06/15/2021
Oncology
Conference Coverage
Real-World Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer
06/14/2021
More than half of patients with metastatic castration-sensitive prostate cancer did not receive first-line treatment regimens associated with improved survival compared with ADT alone in the community practice setting.
More than half of patients with metastatic castration-sensitive prostate cancer did not receive first-line treatment regimens associated with improved survival compared with ADT alone in the community practice setting.
More than half of patients with...
06/14/2021
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

September 18 ⁠–⁠ September 20
September 21 ⁠–⁠ September 22
AMP Europe
September 30 ⁠–⁠ October 2
October 1 ⁠–⁠ October 2
SAWC Fall
October 2 ⁠–⁠ October 5
October 5 ⁠–⁠ October 6
SMASH
October 14 ⁠–⁠ October 16
Lymphoma, Leukemia, and Myeloma
October 16 ⁠–⁠ October 19
October 19 ⁠–⁠ October 20
October 26 ⁠–⁠ October 27
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use